Mangoceuticals, Inc. (MGRX) · Peers
Mangoceuticals against the 13 other companies here in its SEC industry, Services-Misc Health & Allied Services, Nec. Each figure is the one on the company's own page; the median is the peers', and the rank is among all 14, highest first.
Measure by measure
| Measure | MGRX | Peer median | Rank |
|---|---|---|---|
| Market value | $6.21M | median $417.58M | 13 of 13 |
| P/S | 19.7× | median 1.7× | 3 of 13 |
| FCF yield | -62.6% | median 4.8% | 12 of 12 |
| Gross margin | 54.4% | median 55.0% | 6 of 10 |
| ROIC | -77.3% | median 12.8% | 6 of 6 |
| ROE | -120.6% | median 7.2% | 9 of 10 |
| Current ratio | 0.2× | median 1.9× | 13 of 13 |
| Stock pay / revenue | 688.0% | median 1.0% | 1 of 14 |
Green where Mangoceuticals is on the better side of the median, red where on the worse; no colour where higher is neither, like size or dividend yield.
The peers, largest first
| Company | Market value | P/E | ROIC | Score |
|---|---|---|---|---|
| MGRXMangoceuticals, Inc. | $6.21M | P/E – | -77.3% | 3.4 |
| DVADaVita HealthCare Partners Inc | $11.99B | P/E 14.2× | 18.0% | 7.1 |
| FMSFresenius Medical Care AG | $11.80B | P/E – | – | 4.5 |
| SHCSotera Health Co | $5.11B | P/E 31.2× | – | 5.7 |
| PGNYProgyny, Inc. | $2.12B | P/E 26.9× | 40.9% | 8.4 |
| AGLagilon health, inc. | $1.43B | P/E – | – | 4.6 |
| MCTACharming Medical Ltd | $474.08M | P/E – | – | 3.5 |
| VMDViemed Healthcare Inc | $361.08M | P/E 24.9× | 12.8% | 7.5 |
| PARKPark Dental Partners, Inc. | $91.21M | P/E 95.1× | – | 4.8 |
| MRAIMarpai, Inc. | $83.98M | P/E – | – | 2.5 |
| BRTXBioRestorative Therapies, Inc. | $39.49M | P/E – | – | 4.1 |
| CCELCryo Cell International Inc | $35.07M | P/E – | – | 5.9 |
| PFHOPacific Health Care Organization Inc | $12.03M | P/E 12.3× | 6.4% | 6.2 |
| NIVFNewGenIvf Group Ltd | – | P/E – | -32.4% | 6.0 |
The industry is the Standard Industrial Classification code the company registered with the SEC. It is a broad label: a peer group is a starting point for comparing, not proof that two businesses are alike. None of this is advice.